The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing Manufacture Of Chemicals And Pharamceuticals Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
170 jobs Number of planned job creations
Announcement Date
1 July 2005
Employment effect (start)
1 February 2008
Foreseen end date
31 July 2008
Description
Europe's biggest pharmaceutical company GlaxoSmithKline announced on 1 July 2005 the expansion of its operations in Dresden. On 19 October 2006 it confirmed that the production of influenza-vaccines is to double in 2008, when a new complex of Glaxo's factory will become operational. This will lead to the creation of 170 jobs. In addition to the built-up of more production capacity, a new vaccine will also be developed in Dresden.
Sources
19 October 2006: Frankfurter Allgemeine Zeitung
2 July 2005: MDR.DE
Citation
Eurofound (2005), GlaxoSmithKline, Business expansion in Germany, factsheet number 61883, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/61883.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
